Novel Multiple-Stage Active Antimalarials

Information

  • Research Project
  • 10146947
  • ApplicationId
    10146947
  • Core Project Number
    R01AI141972
  • Full Project Number
    5R01AI141972-03
  • Serial Number
    141972
  • FOA Number
    PA-18-484
  • Sub Project Id
  • Project Start Date
    6/14/2019 - 5 years ago
  • Project End Date
    5/31/2024 - 11 months ago
  • Program Officer Name
    O'NEIL, MICHAEL T
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    5/7/2021 - 3 years ago

Novel Multiple-Stage Active Antimalarials

PROJECT SUMMARY/ABSTRACT Natural products have been notably at the forefront of most approaches to combating many infectious diseases. Many of the natural products have served as template for the design and development of antimalarial drugs currently in the clinic or in the development phase. Recently we have developed a series of novel antimalarial chemical entities inspired by the prodiginine and tambjamine natural products that meet the following key criteria: 1) potent activities against liver stage and blood stage malaria parasites, as well as inhibition of gamete formation; 2) orally efficacious; 3) curative in a single dose; 4) fast-acting; 5) long duration of coverage; and 6) unique chemotype as compared to existing antimalarials likely operate by a novel mechanism(s) of action. The ability to combat multiple stages of the infection with the potential of transmission blocking represents a powerful tool, and one ideally suited to achieve the broadest possible benefit as a renewed malaria eradication effort proceeds. Our proposed work in this application seeks to develop novel, potent, safe, and inexpensive antimalarial drugs for both prevention and treatment of malaria, thus supporting world-wide elimination of the disease. The specific goal of this project is to conduct lead optimization studies to produce lead candidates for full preclinical testing that retain the broad-spectrum features and demonstrate enhanced efficacy, safety and pharmacokinetic profiles that warrant further development.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    462966
  • Indirect Cost Amount
    157087
  • Total Cost
    620053
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NIAID:620053\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    DDR
  • Study Section Name
    Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section
  • Organization Name
    PORTLAND STATE UNIVERSITY
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    052226800
  • Organization City
    PORTLAND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    972070751
  • Organization District
    UNITED STATES